This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...
The National Institute on Aging (NIA) awarded a 3-year, $4,618,216 Cooperative Agreement (CFDA 93.866 - Aging Research) to the University of California, San Diego (UC San Diego) to develop a novel microtubule-stabilizing drug candidate, CNDR-51997, for the treatment of Alzheimer's disease and related neurodegenerative "tauopathy" conditions. The primary objectives are to advance CNDR-51997 through IND-enabling studies and submit an Investigational New Drug (IND) application to the FDA....
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Jillion Therapeutics Inc. aims to identify small molecule compounds that can bind to and modify the biological behavior of tau protein, which is implicated in Alzheimer's disease and other neurodegenerative "tauopathies". The $496,373 award, spanning September 2024 to August 2025, will utilize the company's DNA-encoded library (DEL) drug discovery platform to screen a large chemical...
This Project Grant award of $320,000 from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) is supporting research at the University of Texas Medical Branch at Galveston (UTMB) to investigate the impact of pathological tau protein on alternative polyadenylation (APA) regulation in Alzheimer's disease. The study aims to comprehensively profile APA transcripts and gene expression in mouse primary hippocampal neurons expressing wild-type and mutant tau proteins....
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,100,000 to the University of Texas Medical Branch at Galveston to investigate the mechanisms of pathological tau protein spreading in Alzheimer's disease. The project aims to determine how amyloid-beta oligomers modulate the binding and internalization of toxic tau oligomers at vulnerable synapses, a key process underlying the spatiotemporal progression of tau pathology in the central nervous...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,015,163 to Baylor College of Medicine to develop an in vivo CRISPR/Cas9 screening method to identify regulators of tau protein levels in the mouse brain. The goal is to bypass labor-intensive cell-based screens and directly assess brain-specific regulators of this Alzheimer's disease-associated protein. The award will fund the development of this high-throughput screening approach (Aim 1) and...
This federal Project Grant award in the amount of $560,636 was provided by the National Institute on Aging (CFDA 93.866 - Aging Research) to the Trustees of Indiana University (Indianapolis) to investigate the therapeutic potential of the niacin receptor HCAR2 in mitigating tau pathology associated with tauopathies like Alzheimer's disease and frontotemporal lobar degeneration. The key objectives are to study the effects of HCAR2 activation using the FDA-approved niacin formulation on reducing...
This $1,147,300 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research by Wayne State University to investigate how pathogenic forms of the tau protein interfere with dendritic protein synthesis and contribute to synaptic dysfunction in Alzheimer's disease. The research aims to enrich the understanding of how tau pathology leads to early synaptic alterations in Alzheimer's, with the goal of identifying molecular targets for intervention...
This Project Grant award, with a total funding amount of $431,750, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award is for the development and evaluation of a novel immuno-gene therapy approach using a single-chain fragment variable (scFv) derived from an anti-tau oligomeric complex 1 (TOC1) antibody. The key objectives are to: 1) generate and validate the TOC1-scFv-HaloTag-Proteasome Degradation Signal (PDS)...
This $519,750 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a 2-year research study by the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco. The study aims to explore the underlying molecular mechanisms by which reducing levels of the tau protein can prevent or diminish excitation/inhibition imbalance and network hyperexcitability in the brain. This imbalance has been observed in various...